CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population

Yu Chuen Huang, Marcelo Chen, Ming Wei Lin, Ming Yi Chung, Yen Hwa Chang, William Ji Shian Huang, Tony T. Wu, Jong Ming Hsu, Stone Yang, Yi Ming Arthur Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: The CYP19 gene encodes aromatase-a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa). Methods: Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%. Results: The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83). Conclusions: The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.

Original languageEnglish
Pages (from-to)996-1000
Number of pages5
JournalUrology
Volume69
Issue number5
DOIs
Publication statusPublished - May 1 2007
Externally publishedYes

Fingerprint

Aromatase
Prostatic Neoplasms
Nucleotides
Genotype
Population
Odds Ratio
Confidence Intervals
Haplotypes
Neoplasm Grading
Androstenedione
Estrone
Genes
Testosterone
Estradiol
Blood Cells
Software
Control Groups
DNA
Enzymes

ASJC Scopus subject areas

  • Urology

Cite this

CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population. / Huang, Yu Chuen; Chen, Marcelo; Lin, Ming Wei; Chung, Ming Yi; Chang, Yen Hwa; Huang, William Ji Shian; Wu, Tony T.; Hsu, Jong Ming; Yang, Stone; Chen, Yi Ming Arthur.

In: Urology, Vol. 69, No. 5, 01.05.2007, p. 996-1000.

Research output: Contribution to journalArticle

Huang, YC, Chen, M, Lin, MW, Chung, MY, Chang, YH, Huang, WJS, Wu, TT, Hsu, JM, Yang, S & Chen, YMA 2007, 'CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population', Urology, vol. 69, no. 5, pp. 996-1000. https://doi.org/10.1016/j.urology.2007.02.014
Huang, Yu Chuen ; Chen, Marcelo ; Lin, Ming Wei ; Chung, Ming Yi ; Chang, Yen Hwa ; Huang, William Ji Shian ; Wu, Tony T. ; Hsu, Jong Ming ; Yang, Stone ; Chen, Yi Ming Arthur. / CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population. In: Urology. 2007 ; Vol. 69, No. 5. pp. 996-1000.
@article{672d0a5853ab4828add87c065e3f4a9d,
title = "CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population",
abstract = "Objectives: The CYP19 gene encodes aromatase-a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa). Methods: Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4{\%}, 23.8{\%}, 19.6{\%}, and 53.2{\%}, respectively. The Gleason score was 2 to 5 in 22.9{\%}, 6 to 7 in 53.2{\%}, and 8 to 10 in 23.8{\%}. Results: The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3{\%}) was significantly greater than that in the controls (5.4{\%}; P = 0.015, odds ratio [OR] 2.43, 95{\%} confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95{\%} CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8{\%} versus 6.1{\%}, OR 0.61, 95{\%} CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95{\%} CI 1.10 to 4.83). Conclusions: The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.",
author = "Huang, {Yu Chuen} and Marcelo Chen and Lin, {Ming Wei} and Chung, {Ming Yi} and Chang, {Yen Hwa} and Huang, {William Ji Shian} and Wu, {Tony T.} and Hsu, {Jong Ming} and Stone Yang and Chen, {Yi Ming Arthur}",
year = "2007",
month = "5",
day = "1",
doi = "10.1016/j.urology.2007.02.014",
language = "English",
volume = "69",
pages = "996--1000",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - CYP19 TCT Tri-Nucleotide Del/Del Genotype Is a Susceptibility Marker for Prostate Cancer in a Taiwanese Population

AU - Huang, Yu Chuen

AU - Chen, Marcelo

AU - Lin, Ming Wei

AU - Chung, Ming Yi

AU - Chang, Yen Hwa

AU - Huang, William Ji Shian

AU - Wu, Tony T.

AU - Hsu, Jong Ming

AU - Yang, Stone

AU - Chen, Yi Ming Arthur

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Objectives: The CYP19 gene encodes aromatase-a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa). Methods: Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%. Results: The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83). Conclusions: The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.

AB - Objectives: The CYP19 gene encodes aromatase-a key enzyme involved in the conversion of androstenedione/testosterone to estrone/estradiol. In this study, we analyzed the association between the TCT insertion (Ins)/deletion (Del) and TTTA repeat polymorphisms of CYP19 and prostate cancer (PCa). Methods: Automated sequencer with GeneScan software was used to determine the CYP19 gene polymorphisms in peripheral blood mononuclear cell DNA from 244 patients with PCa and 261 age-matched healthy male controls. The distribution of Stage I to IV was 3.4%, 23.8%, 19.6%, and 53.2%, respectively. The Gleason score was 2 to 5 in 22.9%, 6 to 7 in 53.2%, and 8 to 10 in 23.8%. Results: The frequency of the TCT Del/Del genotype in the Taiwanese patients with PCa (12.3%) was significantly greater than that in the controls (5.4%; P = 0.015, odds ratio [OR] 2.43, 95% confidence interval [CI] 1.23 to 4.80). Individuals with a homozygous A1 (seven TTTA repeats) genotype had a significantly greater risk of developing PCa (OR 1.59, 95% CI 1.04 to 2.44, P = 0.044). The frequency of the Ins-A6 (12 TTTA repeats) haplotype was significantly greater in the control group than in the patient group (9.8% versus 6.1%, OR 0.61, 95% CI 0.38 to 0.97). The OR of developing PCa for men with the homozygous Del-A1 diplotype was 2.31 (95% CI 1.10 to 4.83). Conclusions: The results of our study have shown that the CYP19 TCT Del/Del genotype might be a susceptibility marker for PCa. Men with the Ins-A6 haplotype had a lower risk of developing PCa.

UR - http://www.scopus.com/inward/record.url?scp=34247621265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247621265&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.02.014

DO - 10.1016/j.urology.2007.02.014

M3 - Article

C2 - 17482958

AN - SCOPUS:34247621265

VL - 69

SP - 996

EP - 1000

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -